Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy-Reference-Cited by-同舟云学术

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Published:2020-01-06 Issue:4 Volume:23 Page:330-346
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Shah Anuj¹,Shah Ruchit¹,Kebede Nehemiah¹,Mohamed Ateesha²,Botteman Marc¹^ORCID,Waldeck Reg²,Hussain Arif³⁴

Affiliation:

1. Pharmerit International, Bethesda, MD, USA;

2. Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA;

3. University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;

4. Baltimore VA Medical Center, Baltimore, MD, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1705313

Reference36 articles.

1. American Cancer Society. Key statistics for prostate cancer; 2019 [cited 2019 Jun 6]. Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html#references

2. Use of androgen deprivation therapy in prostate cancer: indications and prevalence

3. Prostate Cancer

4. American Urological Association. Castration-resistant prostate cancer; 2018. [cited 2019 Apr 25]. Available from: https://www.auanet.org/guidelines/prostate-cancer-castration-resistant-guideline#x1929

5. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States;Future Oncology;2024-07-29

2. Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors;Expert Review of Anticancer Therapy;2024-03-12

3. Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study;Targeted Oncology;2024-02-28

4. Adverse events and costs among non-metastatic castration-resistant prostate cancer patients;Journal of Medical Economics;2024-01-08

5. Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer;Journal of Geriatric Oncology;2023-06